Company intelligence / Profile preview
GI Innovation
Seoul, South Korea
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
GI-102 has completed phase 1 clinical trial in the US and Korea and is entering phase 2. The company recently observed excellent anticancer activity in a preclinical pancreatic cancer model combining GI-102 with LM-302 (ADC targeting Claudin18.2).
- Therapeutic areas
- OncologyRare DiseasesMetabolic DisordersImmunology
- Modalities
- Fusion proteinsBispecific antibodies
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Request access →03
Partnerships
LaNova Medicines
Beyond the preview
Go deeper on GI Innovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GI Innovation.